Validation of a simple inductively coupled plasma mass spectrometry method for detecting urine and serum iodine and evaluation of iodine status of pregnant women in Beijing

Yu, Songlin; Yin, Yanzhen; Cheng, Qian; Han, Jun; Cheng, Xinqi; Guo, Ye; Sun, Dandan; Xie, Shaowei; Qiu, Ling

doi:10.1080/00365513.2018.1512150

Cited by 30 publications

(23 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Serum total iodine was analysed by inductively coupled plasma mass spectrometry ICP‐MS, iCAP Q, Thermo Fisher Scientific, Germany) with the use of tellurium for mass bias correction. Serum samples were diluted with 1.5% isopropanol and 7 mmol hydrous ammonium before analysis by the ICP‐MS . The calibration curve was linear from 1 to 1000 μg/L.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Serum iodine concentration in pregnant women and its association with urinary iodine concentration and thyroid function

Pan

Cui

Chen

et al. 2019

Clinical Endocrinology

View full text Add to dashboard Cite

Summary Objective This study aims to evaluate the association of serum iodine concentration (SIC) with urinary iodine concentration (UIC) and thyroid function in pregnant women, as well as to provide the reference range of SIC of pregnant women in iodine‐sufficiency area. Methods Pregnant women were enrolled in the Department of Obstetrics, Tanggu Maternity Hospital, Tianjin from March 2016 to May 2017. Fasting venous blood and spot urine samples were collected. Serum free triiodothyronine (FT3), free thyroxine (FT4), thyroid‐stimulating hormone (TSH), thyroglobulin (Tg), thyroid peroxidase antibody (TPOAb), thyroglobulin antibody (TgAb), UIC and SIC were measured. Results One thousand and ninety‐nine participants were included in this study. The median UIC was 156 μg/L. The median SIC was 108 μg/L, and the 95% reference interval for SIC was 65.6‐164.7 μg/L. SIC was positively correlated with UIC (r = 0.12, P < 0.001), FT3 (r = 0.23, P < 0.001), and FT4 (r = 0.50, P < 0.001) and was inversely correlated with TSH (r = −0.14, P < 0.001). Pregnant women with a SIC < 79.9 μg/L had a higher risk of hypothyroxinemia compared to those with higher SIC (OR = 2.44, 95% CI: 1.31‐4.75). Those having SIC > 138.5 μg/L were more likely to have thyrotoxicosis than those with lower SIC values (OR = 13.52, 95% CI: 4.21‐43.36). Conclusions Serum iodine level is associated with UIC and thyroid function in pregnant women. Low SIC was associated with increased risk for iodine deficiency and hypothyroxinemia, while high SIC was related to excess and thyrotoxicosis.

show abstract

Section: Methodsmentioning

confidence: 99%

“…with the use of tellurium for mass bias correction. Serum samples were diluted with 1.5% isopropanol and 7 mmol hydrous ammonium before analysis by the ICP-MS. 21 The calibration curve was linear from 1 to…”

Section: Serum Iodine Concentrationmentioning

confidence: 99%

Serum iodine concentration in pregnant women and its association with urinary iodine concentration and thyroid function

Pan

Cui

Chen

et al. 2019

Clinical Endocrinology

View full text Add to dashboard Cite

show abstract

“…Urinary iodine concentration was measured with inductively coupled plasma mass spectrometry (ICP-MS) method. The ICP-MS analysis was performed with an iCAP-Q ICP-MS system (Thermo Scientific, Waltham, MA) coupled with an automated sampler (CETAC ASX-520; Thermo Scientific, Waltham, MA) [ 19 ]. Urinary creatinine (Maccura, China, enzymatic method) was measured using an automated chemistry analyzer (Beckman Coulter AU2700, Beckman Coulter, Brea, USA).…”

Section: Methodsmentioning

confidence: 99%

Low urinary iodine is a protective factor of central lymph node metastasis in papillary thyroid cancer: a cross-sectional study

Zeng

Wang

et al. 2021

World J Surg Onc

View full text Add to dashboard Cite

Background An abrupt increase of thyroid cancer has been witnessed paralleling the supplemented iodine intake in formerly iodine-deficient countries. And increased iodine intake has been linked to the rising incidence rate of papillary thyroid cancer (PTC). However, the correlation between iodine and clinicopathological features of PTC has not been well-characterized. This study aimed to investigate the associations between iodine intake and the clinicopathological features of PTC patients. Methods Three hundred and fifty-nine PTC patients who received surgical treatment in Peking Union Medical College Hospital from May 2015 to November 2020 were retrospectively reviewed. The associations between urinary iodine (UI), urinary iodine/creatinine ratio (UI/U-Cr), and the clinicopathological features of PTC were analyzed. Univariate and multivariate analysis were performed to investigate the relationship between UI level and central lymph node metastasis (CLNM). Results There were no significant differences in UI in different groups according to the variables studied, except that patients with CLNM had higher UI level than CLNM(−) patients. No associations were found between UI/U-Cr and clinicopathological features except variant subtypes (classic/follicular). After dividing patients into high-iodine group and low-iodine group, more patients were found to have CLNM in the high-iodine group (p = 0.02). In addition, younger age, larger tumor size, and classic variant were positively correlated with CLNM (p < 0.05). Univariate analysis showed that insufficient iodine intake (≤ 99 μg/L) was associated with decreased CLNM risk in PTC. And after defining insufficient iodine intake as ≤ 109 μg/L and above requirements as ≥ 190 μg/L, multivariate analysis showed that lower iodine was associated with CLNM in total population of PTC (OR 0.53, 95% CI 0.31–0.91) and in PTC < 1 cm (papillary thyroid microcarcinoma, PTMC) (OR 0.43, 95% CI 0.21–0.87). Conclusions Low iodine was a protective factor for CLNM in papillary thyroid cancer, particularly in those < 1 cm. These results indicated that iodine may not only be an initiator of tumorigenesis, but also a promoter of the development of PTC.

show abstract

“…Urinary iodine concentration was measured with inductively coupled plasma mass spectrometry (ICP-MS) method. The ICP-MS analysis was performed with an iCAP-Q ICP-MS system (Thermo Scienti c, Waltham, MA) coupled with an automated sampler (CETAC ASX-520; Thermo Scienti c, Waltham, MA) (18). Urinary creatinine (Maccura, China, enzymatic method) was measured using an automated chemistry analyzer (Beckman Coulter AU2700, Beckman Coulter, Brea, USA).…”

Section: Measurement Of Urinary Iodine and Urinary Creatininementioning

confidence: 99%

Low Urinary Iodine is a Protective Factor of Central Lymph Node Metastasis in Papillary Thyroid Cancer: A Cross-sectional Study

Zeng

Wang

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: An abrupt increase of thyroid cancer has been witnessed paralleling the supplemented iodine intake in formerly iodine-deficient countries. And increased iodine intake has been linked to the rising incidence rate of papillary thyroid cancer (PTC). However, the correlation between iodine and clinicopathological features of PTC has not been well-characterized. This study aimed to investigate the associations between iodine intake and the clinicopathological features of PTC patients.Methods: 359 PTC patients who have received surgical treatment in Peking Union Medical College Hospital from May 2015 to November 2020 were retrospectively reviewed. The associations between urinary iodine (UI), urinary iodine/creatinine ratio (UI/U-Cr) and the clinicopathological features of PTC were analyzed. Univariate and multivariate analysis were performed to investigate the relationship between UI level and central lymph node metastasis (CLNM).Results: There were no significant differences of UI in different groups according to the variables studied, except that patients with CLNM had higher UI level than CLNM(-) patients. No associations were found between UI/U-Cr and clinicopathological features except variant subtypes (classic/follicular). After dividing patients into high-iodine group and low-iodine group, more patients were found to have CLNM in high-iodine group (p=0.017). In addition, younger age, larger tumor size and classic variant positively correlated with CLNM (p<0.05). Univariate analysis showed that insufficient iodine intake (≤ 99 μg/L) were associated with decreased CLNM risk in PTC. And after defining insufficient iodine intake as ≤ 109 μg/L and above requirements as ≥ 190 μg/L, multivariate analysis showed that lower iodine was associated with CLNM in total population of PTC (OR: 0.53, 95 % CI: 0.31 - 0.91) and in PTC < 1cm (papillary thyroid microcarcinoma, PTMC) (OR: 0.43, 95 % CI: 0.21 - 0.87).Conclusions: Low iodine was a protective factor for CLNM in papillary thyroid cancer, particularly in those < 1 cm. These results indicated that iodine may not only be an initiator of tumorigenesis, but also a promoter of the development of PTC.

show abstract

Validation of a simple inductively coupled plasma mass spectrometry method for detecting urine and serum iodine and evaluation of iodine status of pregnant women in Beijing

Cited by 30 publications

References 20 publications

Serum iodine concentration in pregnant women and its association with urinary iodine concentration and thyroid function

Serum iodine concentration in pregnant women and its association with urinary iodine concentration and thyroid function

Low urinary iodine is a protective factor of central lymph node metastasis in papillary thyroid cancer: a cross-sectional study

Low Urinary Iodine is a Protective Factor of Central Lymph Node Metastasis in Papillary Thyroid Cancer: A Cross-sectional Study

Contact Info

Product

Resources

About